OOIR: Observatory of International Research

Papers

(The TQCC of Diabetes Obesity & Metabolism is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24‐week, multicentre, randomized, double‐blind, placebo‐controlled, phase III	449
	213
Disparities in heart failure deaths among people with diabetes in the United States: 1999–2020	155
Anthropometric metabolic subtypes and health outcomes: A data‐driven cluster analysis	121
Superior benefits of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors for diabetic kidney disease: A cohort study	115
Effects of atrasentan on markers of liver function in patients with type 2 diabetes and chronic kidney disease	104
A prospective observational study to evaluate a possible relationship between vitamin K antagonist therapy and risk of peripheral arterial disease in patients with type 2 diabetes	97
Effect of haemodialysis on the pharmacokinetics and pharmacodynamics of evogliptin	88
Response to letter from Du et al. regarding article ‘Sodium‐glucose cotransporter‐2 inhibitor use was associated with lower risks of stroke and cardiac arrest but not ventricular arrhythmias?’	87
	86
Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c	82
Global, regional and country‐specific burden of chronic kidney disease due to type 1 diabetes mellitus: A systematic analysis of the 2021 global disease burden study	77
Trends in pharmacological management of paediatric patients with type 2 diabetes from 2000 to 2023 in German‐speaking countries: Analysis based on the Diabetes Prospective Follow‐up Registry	76
Follow‐up and monitoring programme in children identified in early‐stage type 1 diabetes during screening in the general population of Italy	73
Serum levels of the incretin‐like peptide 26RFa are diminished in women living with obesity and diabetes and restored after sleeve gastrectomy: Results from the prospective pilot RFa	72
Efficacy and safety of diacerein monotherapy in adults with obesity: A randomized, double‐blind, placebo‐controlled trial	68
The effects of antihypertensive drugs on glucose metabolism	68
The benefit of dexamethasone in patients with COVID‐19 infection is preserved in patients with diabetes	66
Association patterns of ketone bodies with the risk of adverse outcomes according to diabetes status	65
Continuous glucose monitoring and all‐cause mortality in insulin‐using population with diabetes and cognitive impairment	65
Comparing clinical outcomes in patients with type 2 diabetes mellitus after ischaemic stroke: Sodium–glucose cotransporter 2 inhibitors users versus non‐users. A propensity score matching National Coh	65
Diabetes, Obesity and Metabolism	64
Normoalbuminuria—is it normal? The association of urinary albumin within the ‘normoalbuminuric’ range with adverse cardiovascular and mortality outcomes: A systematic review and meta‐analysis	64
Liver fibrosis and liver stiffness in patients with obesity and type 1 diabetes	62
Efficacy and safety of high‐dose glucagon‐like peptide‐1, glucagon‐like peptide‐1/glucose‐dependent insulinotropic peptide, and glucagon‐like peptide‐1/glucagon receptor agonists in type 2 diabetes	62

Global deletion of G protein‐coupled receptor 55 impairs glucose homeostasis during obesity by reducing insulin secretion and β‐cell turnover	62
A retrospective analysis of 24‐month real‐world glucose control for children and adolescents with type 1 diabetes using the MiniMed™ 670G insulin pump	61
Impact of sedentary behaviour on glucose concentration in people with type 1 diabetes	60
Correction to “Real‐world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus”	56
Visceral fat mass dynamics in a 2‐year randomized STrength versus ENdurance training trial in people with obesity	56
Once‐weekly semaglutide reduces the risk of cardiovascular events in people with type 2 diabetes and polyvascular disease: A post hoc analysis	56
Type 2 diabetes pharmacotherapy trends in high‐risk subgroups	52
Effects of CB1R inverse agonist, INV‐202, in patients with features of metabolic syndrome. A randomized, placebo‐controlled, double‐blind phase 1b study	48
A review of the safety of sodium‐glucose co‐transporter‐2 inhibitors	47
Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial	47
Issue Information	47
Utility of serum β2‐microglobulin for prediction of kidney outcome among patients with biopsy‐proven diabetic nephropathy	46
Incidence of chronic kidney disease among adults with prediabetes in the CURE‐CKD registry, 2013–2020	46
Plasma fatty acid esters of hydroxy fatty acids and surrogate fatty acid esters of hydroxy fatty acids hydrolysis activity in children with or without obesity and in adults with or without coronary ar	45
Interventions to improve glycaemic control in people living with, and at risk of developing type 2 diabetes	45
Concurrent SGLT2 inhibitor use in patients with type 2 diabetes hospitalised for high‐dose corticosteroid therapy: Mitigated iatrogenic hyperglycaemia	45
Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic	43
The lifetime health and economic burden of obesity in five European countries: what is the potential impact of prevention?	43
GLP‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity	42
Front Cover	42
Non‐alcoholic fatty liver disease‐related risk of cardiovascular disease and other cardiac complications	41
Long‐term adherence to glucose‐lowering medications in adults with diabetes: A data linkage study	41
Efficacy of beinaglutide in the treatment of hepatic steatosis in type 2 diabetes patients with nonalcoholic fatty liver disease: A randomized, open‐label, controlled trial	40
Professional continuous glucose monitoring in patients with diabetes mellitus: A systematic review and meta‐analysis	40
Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study	39
Adaptive bolus calculators for people with type 1 diabetes: A systematic review	39
Current insulin infusion set failure criteria may be too stringent for real‐life settings and may skew infusion set failure outcomes in extended‐wear infusion set studies	38
Efficacy and safety of cofrogliptin once every 2 weeks in Chinese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, phase 3 trial	38
Is composite cardiovascular death or hospitalization for heart failure a valid surrogate for mortality in patients treated with sodium‐glucose cotransporter 2 inhibitors? A correlation meta‐analysis	38
A low n‐6 to n‐3 polyunsaturated fatty acid ratio diet improves hyperinsulinaemia by restoring insulin clearance in obese youth	38
Effect of renin‐angiotensin system antihypertensive medication use on cognitive function in diabetes mellitus with obesity or overweight: An ancillary study to the Action for Health in Diabetes (Look	37
Efficacy and safety of intragastric expandable oral capsules in adults with overweight or obesity: A randomized, double‐blind, placebo‐controlled trial	37
Diabetes, Obesity and Metabolism	37
Positive allosteric γ‐aminobutyric acid type A receptor modulation prevents lipotoxicity‐induced injury in hepatocytesin vitro	37
Impaired awareness of hypoglycaemia: Prevalence and associated factors before and after FreeStyle Libre use in the Association of British Clinical Diabetologists audit	37
Beta cell function and global glucose metabolism are impaired in Dp(16)1Yey mouse model of Down syndrome	37
Cardiorenal benefits of sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in type 2 diabetes without cardiovascular and renal diseases	36
Issue Information	35
	34
Diabetes, Obesity and Metabolism	33
Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysi	33
Safety, tolerability, pharmacokinetic, pharmacodynamic and immunogenicity profiles of Exendin‐4‐IgG4‐Fc in healthy subjects: A phase 1, single‐centre, randomized, double‐blind, dose escalat	33
Combined application of genetic and polygenic risk scores for type 1 diabetes risk prediction	32
Safety and clinical effectiveness of iGlarLixi in people with type 2 diabetes mellitus in Mexico	32
Impact of the hepatoselective glucokinase activator TTP399 on ketoacidosis during insulin withdrawal in people with type 1 diabetes	32
Efficacy and safety of DBPR108 (prusogliptin) as an add‐on to metformin therapy in patients with type 2 diabetes: A 24‐week, multi‐centre, randomized, double‐blind, placebo‐controlled, supe	32
Associations of metabolic syndrome with cognitive function and dementia risk: Evidence from the UK Biobank cohort	31
Comments on ‘Propensity score matching methodology in Riley et al.'s study on type 2 diabetes and obstructive sleep apnoea’	31
	31
Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial	31

Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme	31
Albuminuria‐lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross‐over clinical study	31
The associations of sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors as add‐on to metformin with fracture risk in patients with type 2 diabetes mellitus	30
Cross‐sectional association of metrics derived from continuous glucose monitoring with cognitive performance in older adults with type 2 diabetes	30
Microvascular disease and its association with dementia in patients with type 2 diabetes: A nationwide cohort study in Taiwan	30
SGLT2 inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial	30
Glyburide use is associated with a greater likelihood of mortality or rehospitalization after acute coronary syndrome compared to gliclazide use in adults with type 2 diabetes: A cohort study	30
Development and validation of a novel method for evaluation of multiple islet autoantibodies in dried blood spot using dissociation‐enhanced lanthanide fluorescent immunoassays technology, specific an	29
Getting the measure of the pressure: Optimal assessment of the effects of glucagon‐like peptide‐1 receptor agonists on blood pressure	29
Weight change in patients with new‐onset type 2 diabetes mellitus and its association with remission: Comprehensive real‐world data	29
Generating real‐world evidence on diabetes technology using the CareLink Personal data management system	29
Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP‐1RA‐based weight‐loss therapies	29
Diabetes and incident stroke and mediation by microvascular dysfunction: Pooled analysis of three population‐based studies	29
Targeting the cholinergic anti‐inflammatory pathway for type 2 diabetes prevention: A retrospective cohort study	28
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonistBI456906	28
Five‐year trajectories of HbA1c by age, sex, ethnicity and deprivation in adults with newly diagnosed type 2 diabetes: Observational study in England	28
Time‐in‐range derived from self‐measured blood glucose in people with type 2 diabetes advancing to iGlarLixi: A participant‐level pooled analysis of three phase 3 LixiLan randomi	28
Long‐term safety and efficacy of glucagon‐like peptide‐1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study	27
Longitudinal audit of assessment and pharmaceutical intervention for cardiovascular risk in the Australasian Diabetes Data Network	27
Renal haemodynamic response to sodium‐glucose cotransporter‐2 inhibition does not depend on protein intake: An analysis of three randomized controlled trials	27
Association of single‐point insulin sensitivity estimator index (SPISE) with future cardiovascular outcomes in patients with type 2 diabetes	27
Safety and efficacy of an oral insulin (Capsulin) in patients with early‐stage type 2 diabetes: A dose‐ranging phase 2b study	27
Renal outcomes with sodium‐glucose cotransporter 2 inhibitors in Japanese people with grade 3 chronic kidney disease and type 2 diabetes: Analysis of medical administrative databases	27
Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants	27
Accelerated onset of diabetes in non‐obese diabetic mice fed a refined high‐fat diet	26
Comparative analysis of hospitalization risk for incident heart failure in non‐Hispanic Black versus non‐Hispanic White individuals with type 2 diabetes on empagliflozin (Empa‐AA): Insights from real‐	25
Postprandial renal haemodynamic effects of the dipeptidyl peptidase‐4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes (RENALIS): A predefined subst	25
Glycated haemoglobin, HOMA2‐B, C‐peptide to glucose ratio and type 2 diabetes clusters as predictors for therapy failure in individuals with type 2 diabetes without insulin thera	25
Postnatal glycaemic outcomes in women with high‐risk gestational diabetes: Identifying key predictors for early intervention	25
Once‐weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long‐term cost‐effectiveness analysis based on SUSTAIN 11	25
Front Cover	25
Exploring new frontiers: Effects of psychedelics on neurotransmitter‐regulated glucagon release in pancreatic islets	25
Future diabetes risk can be predicted by the number of abnormal oral glucose tolerance test values during pregnancy	25
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin‐R with the US‐licensed Humulin® R formulation in healthy subjects: Results from the	25
Healthy lifestyle and all‐cause and cause‐specific dementia in individuals with type 2 diabetes and the roles of diabetes duration and insulin use in UK Biobank cohort	24
Effects of intensive treatment of Chinese women with gestational diabetes on the risk of offspring being overweight from 3 to 8 years of age	24
Outcomes of hybrid closed‐loop insulin delivery activated 24/7 versus evening and night in free‐living prepubertal children with type 1 diabetes: A multicentre, randomized clinical trial	24
Nomogram model and risk score to predict 5‐year risk of progression from prediabetes to diabetes in Chinese adults: Development and validation of a novel model	24
Efficacy and safety of ultra‐rapid lispro versus lispro in children and adolescents with type 1 diabetes: The PRONTO‐Peds trial	24
The impact of overweight and obesity on health outcomes in the United States from 1990 to 2021	24
Validation of the Individualized Metabolic Surgery score in predicting long‐term remission of diabetes after duodenal switch‐type procedures	24
Cover Image, Volume 23, Issue 9	23
The impact of metformin on weight and metabolic parameters in patients with obesity: A systematic review and meta‐analysis of randomized controlled trials	23
Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease	23
Investigating the potential non‐authorized use of two different formulations of liraglutide in Europe: A real‐world drug utilization study	23
A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF‐06882961), an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, in	23
Patients with type 1 diabetes are at elevated risk of developing new hypertension, chronic kidney disease and diabetic ketoacidosis after COVID‐19: Up to 40 months’ follow‐up	23
Predictors of diabetes‐related distress before and after FreeStyle Libre‐1 use: Lessons from the Association of British Clinical Diabetologists n	23
Sodium‐glucose co‐transporter‐2 inhibitors: Writing the next chapter of a unique success story	23
A multicentre, double‐blind, placebo‐controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add‐on therapy in type 2 diabetic patients treated w	23
Risk of insulin initiation with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes mellitus: A real‐world claims database study in Japa	22
Impact of time in tight range on all‐cause and cardiovascular mortality in type 2 diabetes: A prospective cohort study	22
Dapagliflozin modulates hepatic lipid metabolism through the proprotein convertase subtilisin/kexin type 9/low density lipoprotein receptor pathway	22
Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta‐analysis	22
Metabolically healthy obesity and cardiovascular events: A risk of obesity	22
Oral TIX100 protects against obesity‐associated glucose intolerance and diet‐induced adiposity	22
Front Cover	22
When can weekly anti‐obesity peptides be used for monthly administration?	22
Unexpected cardiovascular risks of glucagon‐like peptide‐1 receptor agonist and aspirin co‐administration in individuals with obesity, with and without type 2 diabetes: A propensity score matched coho	21
Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo‐controlled study	21
Sotagliflozin for patients with type 2 diabetes: A systematic review and meta‐analysis	21
Increased cardiovascular risk in people with LADA in comparison to type 1 diabetes and type 2 diabetes: Findings from the DPV registry in Germany and Austria	21
Bone marrow metabolism is affected by body weight and response to exercise training varies according to anatomical location	21
Glucose‐dependent insulinotropic polypeptide counteracts diet‐induced obesity along with reduced feeding, elevated plasma leptin and activation of leptin‐responsive and proopiomelanocortin neurons in	21
Enhancing postpartum cardiometabolic health for women with previous gestational diabetes: Next steps and unanswered questions for pharmacological and lifestyle strategies	20
Changes in remnant cholesterol and the incidence of diabetes: Results from two large prospective cohort studies	20
Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes	20
Low levels of soluble neuropilin‐1 were associated with depression in adults with newly diagnosed type 2 diabetes	20
Novel metabolic and inflammatory stratification of overweight/obesity to characterize risks of adverse outcomes: A large population‐based cohort study	20
Identifying diabetogenic drugs using real world health care databases: A Danish and Australian symmetry analysis	20
Polarized macrophages promote gestational beta cell growth through extracellular signal‐regulated kinase 5 signalling	20
Reduction of cardiac adipose tissue volume with short‐term empagliflozin treatment in patients with type 2 diabetes: A substudy from the SIMPLE randomized clinical trial	20
Frequency and sequence of proteinuria positivity and clinical outcomes in patients with diabetes: A nationwide cohort study	20
Altered high‐density lipoprotein composition is associated with risk for complications in type 2 diabetes mellitus in South Asian descendants: A cross‐sectional, case‐control study on lipoprotein subc	20
Association of body roundness index with cardiovascular disease and all‐cause mortality among Chinese adults	20
Growth differentiation factor 15 (GDF15) and semaglutide inhibit food intake and body weight through largely distinct, additive mechanisms	20
Sick days glycaemic outcomes in a cohort of children and adolescents with type 1 diabetes using an AID system—A preliminary report	20
Use of once‐weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE Canada multicentre, prospective, observational study	20
Incidence and risk factors of new‐onset diabetes mellitus: A five‐year follow‐up study in solid organ transplant recipients in Germany	20
Trends in glycaemic control and drug use in males and females with type 2 diabetes: Results of the Australian National Diabetes Audit from 2013 to 2019	20

The interaction effect between BMI, diabetes and age at diabetes onset on the risk of thyroid cancer: A population‐based cohort study in Shanghai, China	20
Diabetes, Obesity and Metabolism	19
Pyridoxamine reduces methylglyoxal and markers of glycation and endothelial dysfunction, but does not improve insulin sensitivity or vascular function in abdominally obese individuals: A randomized do	19
Dual add‐on therapy of gemigliptin and dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin alone: The SOLUTION 2 study	19
Comprehensive evaluation of siRNA therapeutics on Lp(a): A network meta‐analysis	19
Modelling and assessment of glucose‐lactate kinetics in youth with overweight, obesity and metabolic dysfunction‐associated steatotic liver disease: A pilot study	19
Glycaemia and cardiac arrhythmias in people with type 1 diabetes: A prospective observational study	19
Cover Image, Volume 23, Issue 8	19
Challenging the 50‐50 rule for the basal‐bolus insulin ratio in patients with type 2 diabetes who maintain stable glycaemic control	19
Association of lactation with maternal risk of type 2 diabetes: A systematic review and meta‐analysis of observational studies	19
The impact of family history of type 2 diabetes on clinical heterogeneity in idiopathic type 1 diabetes	19
Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes	19
Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?	19
Nasal glucagon is safe and effective in children and adolescents with type 1 diabetes: A real‐world prospective cohort study	19
Cofrogliptin once every 2 weeks as add‐on therapy to metformin versus daily linagliptin in patients with type 2 diabetes in China: A randomized, double‐blind, non‐inferiority trial	18
	18
Predictors of time in target glucose range in real‐world users of the MiniMed 780G system	18
Distribution patterns of intramyocellular and extramyocellular fat by magnetic resonance imaging in subjects with diabetes, prediabetes and normoglycaemic controls	18
Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment	18
Newer glucose‐lowering drugs and risk of suicidal ideation and behaviours: A network meta‐analysis of randomized outcome trials	18
Use of adjunctive glycaemic agents with vascular protective properties in individuals with type 1 diabetes: Potential benefits and risks	18
Integrated safety and efficacy analysis of dasiglucagon for the treatment of severe hypoglycaemia in individuals with type 1 diabetes	18
Risk factor control and incident cardiovascular disease in patients with diabetes: Sex‐specific relations	18
Body composition changes during weight reduction with tirzepatide in the SURMOUNT‐1 study of adults with obesity or overweight	18
Association between the body mass index and risk of cardiovascular events in sodium‐glucose cotransporter 2 inhibitor users compared with dipeptidyl‐peptidase 4 inhibitor users:	18
Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism	18
Efficacy and safety of efpeglenatide in adults with obesity and its associated metabolic disturbance: A systematic review and meta‐analysis of randomized controlled trials	18
Front Cover	18
Long‐term all‐cause mortality of metabolic‐dysfunction associated steatotic liver disease based on body weight phenotypes following acute myocardial infarction: A retrospective cohort study	17
Effectiveness and safety of daily oral semaglutide in people with type 2 diabetes mellitus switching from sulfonylureas: A real‐world retrospective study	17
The effects of kisspeptin on food intake in women with overweight or obesity	17
Associations of body mass index trajectory, waist circumference trajectory, or both with type 2 diabetes mellitus risk in Chinese adults: The China‐PAR project	17
Diabetes, Obesity and Metabolism	17
Developing an automated algorithm for identification of children and adolescents with diabetes using electronic health records from the OneFlorida+ clinical research network	17
Trends in anti‐diabetic medication use, severe hyperglycaemia and severe hypoglycaemia among American Indian and Alaska Native Peoples, 2009–2013	17
Genetic evidence for the effects of glucokinase activation on frailty‐related outcomes: A Mendelian randomisation study	17
Real‐world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: An international, multicentre, 12‐month, prospective observational study	17
Exercise‐related hypoglycaemia induces QTc‐interval prolongation in individuals with type 1 diabetes	17
Integrated biomarker profiling for predicting the response of type 2 diabetes to metformin	17
Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan‐O‐AP and LixiLan‐L‐CN	17
Cover Image, Volume 24, Issue 12	17
Efficacy of topiramate in reducing second‐generation antipsychotic‐associated weight gain among children: A systematic review and meta‐analysis	16
The extent and predictors of off‐label use of GLP‐1 receptor agonists for weight loss management	16
Effects of sodium‐glucose cotransporter‐2 inhibitors in myocardial infarction patients: A systematic review and meta‐analysis	16
The retinopathy‐derived HbA1c threshold of 6.5% for type 2 diabetes also captures the risk of diabetic nephropathy in NHANES	16
Neighbourhood‐level social deprivation and the risk of recurrent heart failure hospitalizations in type 2 diabetes	16
Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial	16
Cardiovascular risk profiles: A cross‐sectional study evaluating the generalizability of the glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials REWIND, LEADER	16
Sex‐specific associations between skeletal muscle mass and incident diabetes: A population‐based cohort study	16
Efficacy and safety of once‐weekly insulin icodec in type 2 diabetes: A meta‐analysis of ONWARDS phase 3 randomized controlled trials	16
Barriers to early diagnosis of chronic kidney disease and use of sodium‐glucose cotransporter‐2 inhibitors for renal protection: A comprehensive review and call to action	16
Glycaemic treatment of newly diagnosed type 2 diabetes	16
Effect of glucagon‐like peptide 1 receptor agonists on albuminuria in adult patients with type 2 diabetes mellitus: A systematic review and meta‐analysis	16
Hypoglycaemia and rebound hyperglycaemia increase left ventricular systolic function in patients with type 1 diabetes	16
Fat‐to‐muscle ratio is associated with insulin resistance and cardiometabolic disorders in adults with type 1 diabetes mellitus	16
	16
An overview of the CANVAS Program and CREDENCE trial: The primary outcomes and key clinical implications for those managing patients with type 2 diabetes	16
Management of the ‘wicked’ combination of heart failure and chronic kidney disease in the patient with diabetes	16
Overweight or obesity, weight variability and the risk of retinopathy in type 1 diabetes	16
Rationale and design of the phase 3a development programme (ONWARDS 1–6 trials) investigating once‐weekly insulin icodec in diabetes	16
Real world use of tirzepatide in the treatment of type 2 diabetes in an Arab population	16
Striving for early effective glycaemic and weight management in type 2 diabetes: A narrative review	16
A clinical overview of non‐alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications—What the non‐specialist needs to know	15
Liraglutide increases islet Ca²⁺ oscillation frequency and insulin secretion by activating hyperpolarization‐activated cyclic nucleotide‐gated channels	15
Efficacy of liraglutide added to sodium‐glucose cotransporter‐2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post‐hoc analysis of LIRA‐ADD2SGLT2i	15
Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses	15
Real‐world use of liraglutide for weight management according to label in the United Kingdom: A cohort study using the Clinical Practice Research Datalink primary care databases	15
Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: A post hoc analysis	15
Impact of a very low‐calorie ketogenic diet on metabolic and microbiota outcomes in post‐bariatric patients and bariatric‐Naïve individuals: A comparative pilot study	15
Glucagon‐like peptide‐1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta‐analysis of randomised controlled trials	15
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial	15
Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta‐analysis including the 2‐year STEP 5 trial	15
One‐year real‐world performance of the DBLG1 closed‐loop system: Data from 3706 adult users with type 1 diabetes in Germany	15
Diabetes, Obesity and Metabolism	14
Morning versus afternoon physical activity and health‐related outcomes in individuals with type 2 diabetes	14
Association of estimated plasma volume and weight loss after long‐term administration and subsequent discontinuation of the sodium‐glucose cotransporter‐2 inhibitor tofogliflozin	14
	14
Survodutide, a glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo‐controlled, dose‐finding,	14
Long‐term efficacy and safety of enavogliflozin in Korean people with type 2 diabetes: A 52‐week extension of a Phase 3 randomized controlled trial	14
Patterns of metformin use and glycated haemoglobin trends among patients with newly diagnosed type 2 diabetes in Alberta, Canada	14
Diabetes, Obesity and Metabolism	14
Perceptions, attitudes and barriers to effective obesity care among people with obesity and health care professionals in India	14
Impact of level 2 hypoglycaemia on neuroaxonal damage biomarker in individuals with type 2 diabetes: A stepwise hypoglycaemic clamp study	14
Cost‐utility analysis of semaglutide for type 2 diabetes after its addition to the National Medical Insurance System in China	14
Real‐world impact of adding a glucagon‐like peptide‐1 receptor agonist compared with basal insulin on metabolic targets in adults living with type 2 diabetes and chronic kidney disease already treated	14
Front Cover	14
ACAD10 is not required for metformin's metabolic actions or for maintenance of whole‐body metabolism in C57BL/6J mice	13
Incident heart failure, arrhythmias and cardiovascular outcomes with sodium‐glucose cotransporter 2 (SGLT2) inhibitor use in patients with diabetes: Insights from a global federated electro	13
Mechanisms underlying the blood pressure‐lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: A secondary analysis of a randomized crossover trial	13
Initial antibiotic therapy for postoperative moderate or severe diabetic foot infections: Broad versus narrow spectrum, empirical versus targeted	13
Retinal vascular density as a potential biomarker of diabetic cerebral small vessel disease	13
Gastric emptying is slower in women than men with type 2 diabetes and impacts on postprandial glycaemia	13
Prevalence of MASLD in children and adolescents with type 1 diabetes: A meta‐analysis	13
Impact of weight loss on obesity‐related complications and direct healthcare costs in Japan: A modelling study	13
Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT‐1 to ‐4 trials	13